A fresh wave of SARS-CoV-2 infections is pushing the case counts across India to record highs even as the authorities vehemently deny the role of any mutant variant behind the sudden surge.
In India, the conversation on herd immunity intensified in July following sero-surveys in New Delhi and Mumbai, two of India’s most populated metros, that showed extensive COVID-19 infections in both cities.
The Hyderabad-based biotechnology firm Bharat Biotech has received the nod from the Drug Controller General of India for conducting phase I and II human clinical trials for India’s first COVID -19 vaccine candidate, code-named as COVAXIN.
The Indian Council of Medical Research (ICMR) has recently approved a rapid antigen detection assay for the diagnosis of COVID-19 using nasal samples. Developed by SD Biosensor, Standard Q COVID-19 Ag detection kit is a rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2.
An at-home breast cancer screening service has been launched by the Niramai Health Analytix in Bengaluru for helping assess breast health in women.
The Indian multinational pharmaceutical company Sun Pharma has commenced a phase II clinical trial on the plant-derived drug AQCH to test its efficacy and safety in COVID-19 patients.